BRPI0916624A2 - anticorpos monoclonais seletivos anti-hepcidina-25, seus usos, bem como método e kit para quantificar a quantidade de proteína hepcidina-25 em uma amostra de tecido ou fluido biológico - Google Patents
anticorpos monoclonais seletivos anti-hepcidina-25, seus usos, bem como método e kit para quantificar a quantidade de proteína hepcidina-25 em uma amostra de tecido ou fluido biológicoInfo
- Publication number
- BRPI0916624A2 BRPI0916624A2 BRPI0916624A BRPI0916624A BRPI0916624A2 BR PI0916624 A2 BRPI0916624 A2 BR PI0916624A2 BR PI0916624 A BRPI0916624 A BR PI0916624A BR PI0916624 A BRPI0916624 A BR PI0916624A BR PI0916624 A2 BRPI0916624 A2 BR PI0916624A2
- Authority
- BR
- Brazil
- Prior art keywords
- hepcidin
- quantifying
- kit
- selective
- protein
- Prior art date
Links
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 title 2
- 102400001151 Hepcidin-25 Human genes 0.000 title 2
- 101800003310 Hepcidin-25 Proteins 0.000 title 2
- 239000013060 biological fluid Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8655708P | 2008-08-06 | 2008-08-06 | |
| PCT/US2009/052044 WO2010017070A1 (en) | 2008-08-06 | 2009-07-29 | Anti-hepcidin-25 selective antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0916624A2 true BRPI0916624A2 (pt) | 2015-12-01 |
Family
ID=41165490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0916624A BRPI0916624A2 (pt) | 2008-08-06 | 2009-07-29 | anticorpos monoclonais seletivos anti-hepcidina-25, seus usos, bem como método e kit para quantificar a quantidade de proteína hepcidina-25 em uma amostra de tecido ou fluido biológico |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8609817B2 (enExample) |
| EP (1) | EP2328931B1 (enExample) |
| JP (1) | JP5730200B2 (enExample) |
| KR (1) | KR101462307B1 (enExample) |
| CN (1) | CN102112489B (enExample) |
| AU (1) | AU2009279865B2 (enExample) |
| BR (1) | BRPI0916624A2 (enExample) |
| CA (1) | CA2733497C (enExample) |
| DK (1) | DK2328931T3 (enExample) |
| EA (1) | EA201170312A1 (enExample) |
| ES (1) | ES2432018T3 (enExample) |
| IL (1) | IL210643A (enExample) |
| MX (1) | MX2011001363A (enExample) |
| NZ (1) | NZ590863A (enExample) |
| PL (1) | PL2328931T3 (enExample) |
| PT (1) | PT2328931E (enExample) |
| UA (1) | UA103032C2 (enExample) |
| WO (1) | WO2010017070A1 (enExample) |
| ZA (1) | ZA201100261B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102584947B (zh) * | 2003-04-01 | 2014-03-12 | 国家健康医学研究所 | 针对丙型肝炎病毒e1e2 复合体的抗体、hcv 颗粒的组合物和药物组合物 |
| AR069062A1 (es) * | 2007-11-02 | 2009-12-23 | Lilly Co Eli | Anticuerpo anti-hepcidina |
| DK2606061T3 (da) | 2010-08-16 | 2017-11-06 | Pieris Pharmaceuticals Gmbh | Bindingsproteiner til hepcidin |
| AU2012350654C1 (en) | 2011-12-12 | 2018-05-10 | Pieris Ag | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation |
| US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
| US20140120560A1 (en) * | 2012-10-26 | 2014-05-01 | Claresa Levetan | Generation of new pancreatic beta cells |
| US10429390B2 (en) | 2012-12-18 | 2019-10-01 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
| JP6463331B2 (ja) * | 2013-03-15 | 2019-01-30 | イントリンシック ライフサイエンシズ リミテッド ライアビリティ カンパニー | 抗ヘプシジン抗体およびその使用 |
| US9816997B2 (en) * | 2013-10-03 | 2017-11-14 | Biocare Medical, Llc | Anti-SOX10 antibody systems and methods |
| JPWO2016027469A1 (ja) * | 2014-08-21 | 2017-06-01 | 国立大学法人旭川医科大学 | ヘプシジンのスプライシングバリアント並びに該バリアントを指標とした癌の診断方法 |
| AU2015321462B2 (en) * | 2014-09-22 | 2020-04-30 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| WO2016146587A1 (en) | 2015-03-13 | 2016-09-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Hepcidin antagonists for use in the treatment of inflammation |
| US11692027B2 (en) | 2016-09-28 | 2023-07-04 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
| EP3559039A1 (en) | 2016-12-22 | 2019-10-30 | Università Degli Studi Magna Graecia Catanzaro | A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43 |
| WO2018234538A1 (en) | 2017-06-23 | 2018-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Hepcidin antagonist or agonist for use in the treatment of dysregulation of mo and/or mn metabolism |
| CN109948371B (zh) * | 2019-03-07 | 2021-06-25 | 深圳市智税链科技有限公司 | 为区块链节点发放身份证书的方法及相关装置 |
| JP2022549506A (ja) | 2019-09-27 | 2022-11-25 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症および関連状態を処置するための方法 |
| EP4149548A4 (en) | 2020-05-13 | 2024-05-08 | Disc Medicine, Inc. | ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| JPWO2022154121A1 (enExample) * | 2021-01-18 | 2022-07-21 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1210418B1 (en) | 1999-06-02 | 2010-08-18 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6262247B1 (en) | 1999-08-30 | 2001-07-17 | Incyte Genomics, Inc. | Polycyclic aromatic hydrocarbon induced molecules |
| JP4944360B2 (ja) * | 2001-05-25 | 2012-05-30 | アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） | 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用 |
| CN1173737C (zh) | 2002-10-21 | 2004-11-03 | 钱忠明 | Hepcidin(海魄喜定)在制药中的应用 |
| US7411048B2 (en) * | 2002-11-19 | 2008-08-12 | Drg International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids |
| EP1578254B1 (en) | 2002-11-19 | 2013-03-06 | DRG International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor |
| US8017737B2 (en) | 2002-11-19 | 2011-09-13 | Hasan Kulaksiz | Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor |
| US20050033029A1 (en) | 2003-06-30 | 2005-02-10 | Jin Lu | Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses |
| CA2537668A1 (en) | 2003-09-29 | 2005-04-14 | Biosite Incorporated | Methods and compositions for the diagnosis of sepsis |
| AU2003271174A1 (en) * | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| US7723063B2 (en) * | 2004-04-28 | 2010-05-25 | Intrinsic Lifesciences | Methods for measuring levels of bioactive human hepcidin |
| NZ560976A (en) | 2005-03-11 | 2011-06-30 | Univ Johns Hopkins | Biomarkers for ovarian cancer and endometrial cancer: hepcidin |
| MX2009008104A (es) | 2007-02-02 | 2009-08-07 | Amgen Inc | Hepcidina, antagonistas de hepcidina y metodos de uso. |
| GR1006896B (el) * | 2007-08-24 | 2010-07-20 | Ελληνικο Ινστιτουτο Παστερ, | Μεθοδος παραγωγης μιας πεπτιδικης ορμονης |
| CN101903044A (zh) | 2007-10-02 | 2010-12-01 | 国家健康与医学研究院 | 对人铁调素具有特异性的抗原结合蛋白 |
| AR069062A1 (es) * | 2007-11-02 | 2009-12-23 | Lilly Co Eli | Anticuerpo anti-hepcidina |
| EP2620448A1 (en) | 2008-05-01 | 2013-07-31 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
-
2009
- 2009-07-29 KR KR1020117002748A patent/KR101462307B1/ko not_active Expired - Fee Related
- 2009-07-29 CA CA2733497A patent/CA2733497C/en active Active
- 2009-07-29 PL PL09790908T patent/PL2328931T3/pl unknown
- 2009-07-29 EA EA201170312A patent/EA201170312A1/ru unknown
- 2009-07-29 UA UAA201101111A patent/UA103032C2/uk unknown
- 2009-07-29 BR BRPI0916624A patent/BRPI0916624A2/pt not_active IP Right Cessation
- 2009-07-29 NZ NZ590863A patent/NZ590863A/xx not_active IP Right Cessation
- 2009-07-29 ES ES09790908T patent/ES2432018T3/es active Active
- 2009-07-29 PT PT97909089T patent/PT2328931E/pt unknown
- 2009-07-29 US US13/055,201 patent/US8609817B2/en not_active Expired - Fee Related
- 2009-07-29 DK DK09790908.9T patent/DK2328931T3/da active
- 2009-07-29 WO PCT/US2009/052044 patent/WO2010017070A1/en not_active Ceased
- 2009-07-29 AU AU2009279865A patent/AU2009279865B2/en not_active Ceased
- 2009-07-29 JP JP2011522119A patent/JP5730200B2/ja not_active Expired - Fee Related
- 2009-07-29 MX MX2011001363A patent/MX2011001363A/es active IP Right Grant
- 2009-07-29 CN CN200980129864.0A patent/CN102112489B/zh not_active Expired - Fee Related
- 2009-07-29 EP EP09790908.9A patent/EP2328931B1/en active Active
-
2011
- 2011-01-10 ZA ZA2011/00261A patent/ZA201100261B/en unknown
- 2011-01-13 IL IL210643A patent/IL210643A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009279865B2 (en) | 2013-10-10 |
| EP2328931B1 (en) | 2013-08-14 |
| HK1156326A1 (en) | 2012-06-08 |
| PL2328931T3 (pl) | 2014-01-31 |
| UA103032C2 (uk) | 2013-09-10 |
| CA2733497A1 (en) | 2010-02-11 |
| EP2328931A1 (en) | 2011-06-08 |
| MX2011001363A (es) | 2011-04-26 |
| PT2328931E (pt) | 2013-11-07 |
| US20110189190A1 (en) | 2011-08-04 |
| KR101462307B1 (ko) | 2014-11-17 |
| IL210643A0 (en) | 2011-03-31 |
| ES2432018T3 (es) | 2013-11-29 |
| IL210643A (en) | 2015-09-24 |
| JP2011530514A (ja) | 2011-12-22 |
| CN102112489A (zh) | 2011-06-29 |
| NZ590863A (en) | 2012-10-26 |
| JP5730200B2 (ja) | 2015-06-03 |
| CN102112489B (zh) | 2014-05-14 |
| AU2009279865A1 (en) | 2010-02-11 |
| KR20110031963A (ko) | 2011-03-29 |
| CA2733497C (en) | 2015-06-02 |
| US8609817B2 (en) | 2013-12-17 |
| EA201170312A1 (ru) | 2012-03-30 |
| DK2328931T3 (da) | 2013-09-30 |
| WO2010017070A1 (en) | 2010-02-11 |
| ZA201100261B (en) | 2012-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0916624A2 (pt) | anticorpos monoclonais seletivos anti-hepcidina-25, seus usos, bem como método e kit para quantificar a quantidade de proteína hepcidina-25 em uma amostra de tecido ou fluido biológico | |
| BRPI0716163A2 (pt) | mÉtodos e kits para detectar fluido cÉrebro-espinhal em uma amostra | |
| BR112012013362A2 (pt) | sistema para a determinação de um valor para pelo menos um parâmetro que descreve a atividade microbiana de organismos biológicos individuais em uma amostra de líquido, e, método para a determinação da atividade microbiana em uma amostra de líquido | |
| BRPI0920261A2 (pt) | Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica | |
| BRPI0813985A2 (pt) | anticorpos humanos para cd20 humana e método para seu uso. | |
| BRPI0821148A2 (pt) | Dispositivo e método para análise microbiológica de amostras biológicas | |
| WO2008021290A3 (en) | Organ-specific proteins and methods of their use | |
| BRPI0807532A2 (pt) | Fluido tensoativo viscoelástico multicomponente e método de utilização como um fluido de fraturamento | |
| BR112012009846B8 (pt) | método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige | |
| SI3156422T1 (sl) | Človeška protitelesa z visoko afiniteto do PCSK9 | |
| BRPI0807132A2 (pt) | enzimas para o tratamento de lignocelulósicos, ácidos nucléicos que codificam as mesmas, e metodos e uso das mesmas | |
| DK2084519T3 (da) | Røntgenfluorescens-analysefremgangsmåde | |
| EP2015707A4 (en) | REINFORCED BIOLOGICAL FABRIC | |
| IT1406051B1 (it) | Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo. | |
| BRPI0722092A2 (pt) | Proteínas de plantas antifúngicas e métodos para seu uso | |
| EP2319937A4 (en) | METHOD FOR MEASURING BLOOD COMPONENTS ON THE BASIS OF HEMOLYSED WHOLE BLOOD AND KIT FOR THE PROCESS | |
| EP2116837A4 (en) | INSTRUMENT FOR MEASURING THE CONCENTRATION OF PARTICLES IN A LIQUID, MEASURING METHOD AND MEASUREMENT PROGRAM | |
| BRPI0916101A2 (pt) | "método para determinar o estágio de uma gravidez, dispositivo adaptado para detectar os níveis/a quantidade de hpl ou de um fragmento do mesmo em uma amostra de fluido corpóreo derivado de uma fêmea humana, kit e uso de um anticorpo anti-hpl" | |
| BRPI0920695A2 (pt) | detecção de ácido nucleico npm1 em fluidos corpóreos acelulares | |
| BR112013002041A2 (pt) | composição de reagente multiuso e método para determinar simultaneamente as concentrações de pelo menos dois analitos em uma amostra de água | |
| BRPI0921140A2 (pt) | sistema e método de diagnóstico de doenças em bovinos usando análise de auscuta | |
| BRPI0814631A2 (pt) | Adesivo, método para aderir tecido biológico, kit, e artigo. | |
| PT2294176T (pt) | Adaptador de câmara de amostra, em particular para a criopreservação de amostras biológicas | |
| BRPI1009460A2 (pt) | domínio de ligação do anticorpo, anticorpo, uso de um domínio de ligação ou anticorpo, método para detectar a presença de células cancerígenas em uma amostra. | |
| BRPI0820900A2 (pt) | Promotores de proteínas quiméricas e ricas em prolina para expressão em plantas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |